FDA Clears Bria-PROS+ Immunotherapy Trial in Prostate Cancer
FDA Clears Bria-PROS+ Immunotherapy Trial in Prostate Cancer Targeted Oncology
FDA approves Replimune melanoma drug previously rejected twice
FDA approves Replimune melanoma drug previously rejected twice STAT
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy…